Global leader in antibiotics and a division of Swiss multinational pharma company Novartis, Germany-based Sandoz has signed a contract to acquire GlaxoSmithKline’s (GSK) cephalosporin antibiotics.
Cambridge-based global, science-led biopharmaceutical company AstraZeneca and German manufacturer of viral vaccines and biologics IDT Biologika have signed a Letter of Intent (LOI) to increase Europe’s Covid-19 vaccine manufacturing capability.
The U.S. Food and Drug Administration (FDA) has approved Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to moderate Covid-19 patients.
Ocugen, a Pennsylvania-based pharmaceutical company, has signed an agreement with Bharat Biotech, an Indian pharma developer of COVAXIN, a Covid-19 vaccine, to distribute the vaccine in the US.
WuXi STA, a subsidiary of Chinese pharmaceutical company WuXi AppTec, has agreed to buy the Couvet, Switzerland-based manufacturing facility from Bristol Myers Squibb.
French pharma giant Sanofi has entered into an agreement with BioNTech, to manufacture the Covid-19 vaccine co-developed by BioNTech and Pfizer.
Chinese pharmaceutical company Innovent Biologics has signed an out-license agreement with Etana Biotechnologies to develop and commercialise cancer drug BYVASDA (Bevacizumab Biosimilar) in Indonesia.
Thermo Fisher Scientific announced the acquisition of Henogen, a Belgian viral vector manufacturing business belonging to Groupe Novasep, for about €725m ($875m) in cash.
Fujifilm is set to invest about $2bn to build a new large-scale cell culture production site for biopharmaceuticals in the US.
Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the Covid-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.